Surender Singh

Dr. Surender Singh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
SSSurender Singh
Surender Singh
STSunil Taneja
Sunil Taneja
PTPuneeta Tandon
Puneeta Tandon
ABAkash Bansal
Akash Bansal
UGUjjwal Gorsi
Ujjwal Gorsi
VSVirendra Singh
Virendra Singh

20 February 2024 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
BPBijaya K. Padhi
Bijaya K. Padhi
APAravind Gandhi P
Aravind Gandhi P
MSMokanpally Sandeep
Mokanpally Sandeep
MSMuhammad A. Shamim
Muhammad A. Shamim
ADArka De
Arka De
STSunil Taneja
Sunil Taneja

30 March 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PTPuneeta Tandon
Puneeta Tandon
SWSarah Wang
Sarah Wang
MKMoon Young Kim
Moon Young Kim
BHBart Van Hoek
Bart Van Hoek
DBDaphne Bot
Daphne Bot
Aldo J. Montano-LozaAldo J. Montano-Loza
Aldo J. Montano-Loza
Background: Sarcopenia is associated with increased mortality in patients awaiting liver transplant (LT), but the impact of sarcopenia on cirrhosis progression remains under‐evaluated. Aims: We aimed to explore the relationship between sarcopenia and the risk of cirrhosis progression, mortality and hospitalisation in compensated and decompensated cirrhosis. Methods: Sarcopenia was measured using the skeletal muscle index (SMI) obtained from abdominal CT imaging at the 3rd lumbar vertebra (L3). Progression of cirrhosis was defined by an increase in clinical stage from baseline using the D'Amico classification. Factors associated with progression or death, death alone and hospitalisation were evaluated with univariate and multivariate Cox regression models. Results: One thousand six hundred and twenty‐four adult patients with cirrhosis from five centres across Europe, North America and Asia were included. Mean age was 54 ± 9 years, 26% of patients were female, 31% had compensated disease and mean MELD‐Na was 15 ± 7. With separate analyses for compensated and decompensated cirrhosis, sarcopenia was independently associated with the risk of progression or death (aHR 1.43, 95% CI 1.14–1.79, p = 0.002) and death alone (aHR 1.55, 95% CI 1.19–2.03, p = 0.001) only in decompensated cirrhosis. Sarcopenia was independently associated with unplanned hospitalisation in both compensated (aHR 1.70, 95% CI 1–15‐2.51, p = 0.010) and decompensated cirrhosis (aHR 1.32, 95% CI 1.08–1.63, p = 0.007). Conclusions: Sarcopenia was independently associated with cirrhosis progression or death and death alone in decompensated cirrhosis. Future studies are needed to evaluate the possibility of slowing cirrhosis disease progression by reversing or preventing sarcopenia.

1 May 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
SSSurender Singh
Surender Singh
STSunil Taneja
Sunil Taneja
PTPuneeta Tandon
Puneeta Tandon
ADArka De
Arka De
NVNipun Verma
Nipun Verma
VSVirendra Singh
Virendra Singh

8 February 2025 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
GVGerlin Varghese
Gerlin Varghese
AJAshima Jamwal
Ashima Jamwal
DSDeepika Sarawat
Deepika Sarawat
SSSurender Singh
Surender Singh
NTNidhi Tejan
Nidhi Tejan
CSChinmoy Sahu
Chinmoy Sahu

1 January 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
HGHimanshu Gupta
Himanshu Gupta
NNNeha Nigam
Neha Nigam
SSSurender Singh
Surender Singh
ARAkash Roy
Akash Roy
RDRadha K. Dhiman
Radha K. Dhiman